DYN - Dyne Therapeutics, Inc.

Insider Sale by Kersten Dirk (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Kersten Dirk, serving as Dir at Dyne Therapeutics, Inc. (DYN), sold 99,613 shares at $20.35 per share, for a total transaction value of $2,027,158.00. Following this transaction, Kersten Dirk now holds 4,544,773 shares of DYN.

This sale represents a 2.00% decrease in Kersten Dirk's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, April 15, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 17, 2026, 2 days after the trade was made.

Dyne Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Kersten Dirk

Kersten Dirk

Dir

Dirk Kersten is a Managing Partner at Forbion, where he manages the Forbion Growth Opportunities Fund and plays a key role in the investment team with expertise in fund management, deal making, portfolio management, and exit strategies.[[1]](https://forbion.com/team/dirk-kersten/) He joined Forbion in 2018, is a physicist by training, and previously served as a Partner at Gilde Healthcare Partners, leading their Boston office, and as Managing Director at INKEF Capital, overseeing healthcare investments including Dyne Therapeutics (NASDAQ: DYN).[[1]](https://forbion.com/team/dirk-kersten/) Kersten serves as a Director on the Board of Directors at Dyne Therapeutics, Inc. (DYN), a biopharmaceutical company developing therapies for serious muscle diseases, and is listed as a director and 10% owner.[[3]](https://www.tipranks.com/experts/insiders/dirk-kersten)[[4]](https://www.dyne-tx.com/about-us/)[[5]](https://www.gurufocus.com/insider/131775/dirk-kersten) He has led investments in companies like Ascendis Pharma, Profibrix, Lanthio Pharma, and Nightbalance, and currently sits on the boards of Synox Therapeutics and NorthSea Therapeutics.[[1]](https://forbion.com/team/dirk-kersten/) Recently, as a director, he sold shares worth over $127,000 under a Rule 10b5-1 plan, with holdings indirectly through Forbion Capital Fund IV.[[2]](https://www.investing.com/news/insider-trading-news/dyne-therapeutics-director-sells-over-127k-in-company-stock-93CH-3637125)

View full insider profile →

Trade Price

$20.35

Quantity

99,613

Total Value

$2,027,158.00

Shares Owned

4,544,773

Trade Date

Wednesday, April 15, 2026

6 days ago

SEC Filing Date

Friday, April 17, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Dyne Therapeutics, Inc.

Company Overview

No company information available
View news mentioning DYN

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5720459

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime